Coherus BioSciences, Inc. logo
Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody
January 10, 2022 07:30 ET | Coherus BioSciences, Inc.
•  Coherus and Junshi Biosciences plan to evaluate the toripalimab + JS006 combinationin clinical trials in multiple tumor types •  Combinations of PD-1 + TIGIT inhibitors have potential to expand...
Coherus BioSciences, Inc. logo
Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
December 20, 2021 07:59 ET | Coherus BioSciences, Inc.
- Approved for all eligible indications of the reference biological product, Humira® (adalimumab) - - YUSIMRY is Coherus' second FDA-approved product - REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE...
AMR Logo.png
Biotech Ingredients Market Size to Reach $75.3 Billion by 2028 | CAGR: 4.8%: AMR
June 14, 2021 10:36 ET | Allied Market Research
Portland, OR, June 14, 2021 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global biotech ingredients market was pegged at $51.3 billion in 2020 and is...
sandos-logo.jpg
US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case
May 17, 2021 10:44 ET | Novartis Pharma AG
Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients Sandoz is disappointed US patients affected by...
New ACR White Paper Highlights Health Care Challenges Affecting the Rheumatic Disease Community
May 12, 2021 12:28 ET | American College of Rheumatology
Atlanta, May 12, 2021 (GLOBE NEWSWIRE) -- The American College of Rheumatology (ACR) today announced the launch of a new white paper, “Rheumatic Diseases in America: Confronting the Challenge,”...
Coherus BioSciences, Inc. logo
Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review
February 17, 2021 07:30 ET | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”) has...
ERIC Releases Groundbreaking Research Showing Significant Savings from Biosimilars
April 07, 2020 11:14 ET | The ERISA Industry Committee
Washington, DC, April 07, 2020 (GLOBE NEWSWIRE) -- The ERISA Industry Committee (ERIC) released groundbreaking research, part of a larger initiative examining the impact of biosimilars on the health...
Reports and Data.jpeg-01
Ulcerative Colitis Drug Market To Reach USD 10.25 Billion By 2027 | Reports And Data
February 03, 2020 15:00 ET | Reports and Data
New York, Feb. 03, 2020 (GLOBE NEWSWIRE) -- The global ulcerative colitis drug market is forecast to reach USD 10.25 Billion by 2027, according to a new report by Reports and Data. Ulcerative...
Community Oncology Alliance Releases Six New Position Statements
September 18, 2019 12:50 ET | Community Oncology Alliance
Washington, DC, Sept. 18, 2019 (GLOBE NEWSWIRE) -- The Community Oncology Alliance (COA) Board of Directors approved six new Position Statements for public release. A unanimous vote at this week’s...
Fior-Markets-Logo.jpg
Global Erythropoietin Drugs Market is Expected to Reach USD 18.67 Billion by 2025 : Fior Markets
August 26, 2019 08:12 ET | Fior Markets
New Jersey, NJ, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Rising prevalence of anaemia caused due to chronic diseases such as cancer, HIV AIDS, chronic kidney disease is driving the global demand for the...